GO:0032007 negative regulation of TOR signaling: Growth Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032007 (negative regulation of TOR signaling) describes any process that stops, prevents, or reduces the frequency, rate or extent of TOR signaling, a central growth-control pathway.
• The TOR kinase nucleates two distinct complexes, TORC1 and TORC2; negative regulation of TOR signaling most often refers to dampening TORC1 output toward anabolic growth and translation.
• Endogenous brakes on TOR signaling include feedback loops, phosphatases, microRNAs, and stress-responsive proteins that tune pathway output to nutrient and energy status.
• Dysregulated negative regulation of TOR signaling is linked to cancer, metabolic disease, viral immune evasion, and reproductive disorders.
• Experimentally, negative regulation of TOR signaling is probed with rapamycin, phospho-specific antibodies against TOR substrates, and genetic perturbation of upstream regulators.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of negative regulators of TOR signaling in disease-relevant cell types.
Description
GO:0032007, negative regulation of TOR signaling, is a Gene Ontology biological process term that captures any cellular mechanism which stops, prevents, or reduces the frequency, rate or extent of TOR signaling. TOR (target of rapamycin) is a conserved serine/threonine kinase that couples nutrient, energy, and growth-factor cues to anabolic processes such as protein synthesis, ribosome biogenesis, and cell growth. Because unrestrained TOR activity drives proliferation and metabolic reprogramming, cells have evolved multiple layers of negative regulation to keep the pathway within a physiological range. Mechanistically, negative regulation of TOR signaling can occur at the level of the TOR kinase complexes themselves, through upstream repressors such as the TSC complex and REDD1, through phosphatases that reverse activating phosphorylations, or through feedback loops that attenuate upstream PI3K/AKT signaling. For example, PI3K signaling controls PTEN translation to maintain pathway homeostasis, illustrating how negative regulation is embedded within the same network it restrains. In plants, a negative feedback loop of TOR signaling balances growth against stress-response trade-offs, showing that this regulatory logic is evolutionarily deep. For researchers, GO:0032007 matters because it defines the conceptual and experimental space in which pathway output is constrained. Loss of negative regulation can convert a normal growth signal into oncogenic or pathological hyperactivation, whereas excessive negative regulation can suppress growth, impair immunity, or disrupt tissue homeostasis. Understanding which genes execute negative regulation of TOR signaling, and how they are wired, is therefore central to cancer biology, immunometabolism, virology, and aging research.
negative regulation of TOR signaling At A Glance
| GO ID | GO:0032007 |
|---|---|
| GO term | negative regulation of TOR signaling |
| Ontology | biological_process |
| Synonym | down regulation of TOR signaling pathway; inhibition of TOR signaling pathway; negative regulation of target of rapamycin signaling pathway; negative regulation of TOR signaling cascade |
| Major function | Dampens TOR kinase pathway output to balance growth, translation, and stress responses |
| Key upstream inputs | Nutrient status, energy charge, growth-factor signaling, hypoxia, and viral infection |
| Representative negative regulators | TSC1/TSC2, PTEN, REDD1 (DDIT4), LRPPRC, miR-7, and feedback phosphatases |
| Pathological relevance | Cancer, metabolic disorders, viral immune evasion, and reproductive disease |
| Experimental readouts | Phospho-S6K1, phospho-4E-BP1, phospho-AKT, and rapamycin sensitivity |
What Is GO:0032007?
In our own words, GO:0032007 (negative regulation of TOR signaling) is the biological process by which a cell reduces the intensity, duration, or frequency of signal transduction through the TOR kinase pathway. It includes any molecular event that inhibits TOR complex assembly, blocks TOR kinase activity, promotes dephosphorylation of TOR substrates, or engages feedback loops that lower upstream inputs to TOR. The term is deliberately broad: it covers transcriptional, post-transcriptional, translational, and post-translational brakes on TOR signaling, as long as the net outcome is a decrease in TOR pathway output.
Why Is negative regulation of TOR signaling Important in Cell Biology?
Negative regulation of TOR signaling is important because TOR sits at the decision point between growth and conservation. When negative regulation fails, cells can become hypersensitive to nutrients and growth factors, driving tumorigenesis, metabolic dysfunction, and immune dysregulation. Conversely, when negative regulation is too strong, organisms may fail to grow, mount effective antiviral responses, or maintain reproductive and tissue functions. The term therefore provides a unifying framework for understanding how cells avoid runaway anabolism while still responding to environmental cues.
• Defines the molecular brakes that prevent uncontrolled TOR-driven growth and proliferation.
• Explains how cells balance growth against stress-response trade-offs under fluctuating nutrients.
• Provides mechanistic insight into cancer, where loss of negative regulators such as PTEN or TSC1/2 hyperactivates TOR.
• Links TOR signaling to viral pathogenesis, as viruses can manipulate autophagy and TOR-linked proteins to evade immunity.
• Connects TOR regulation to reproductive biology, including follicle development and polycystic ovary syndrome models.
• Underpins aging research, where reduced TOR signaling extends lifespan in model organisms.
• Guides pharmacology, since rapamycin and rapalogs act by inhibiting TOR and mimic negative regulation.
• Offers biomarkers such as phospho-S6K1 and phospho-4E-BP1 for monitoring pathway suppression.
• Supports immunometabolism studies where TOR suppression shapes antiviral and inflammatory responses.
• Enables synthetic biology and CRISPR screens to identify new negative regulators of TOR signaling.
What Happens During negative regulation of TOR signaling?
Sensing of nutrient and energy status
In simple terms: The cell first checks whether it has enough nutrients and energy before deciding to grow.
Negative regulation of TOR signaling begins with sensors that detect amino acids, glucose, oxygen, and energy charge. When nutrients are scarce or energy is low, these sensors transmit inhibitory signals to TOR complex 1 (TORC1), reducing its ability to phosphorylate downstream substrates. Hypoxia, for instance, induces miR-7, which targets REDD1 and thereby modulates mTOR signaling, illustrating how environmental stress feeds into negative regulation. In plants, a negative feedback loop of TOR signaling balances growth and stress-response trade-offs, showing that nutrient sensing is coupled to growth restraint across kingdoms.
Inhibition of TORC1 assembly and kinase activity
In simple terms: Once the cell decides to slow down, it prevents TOR from assembling with its partners or directly blocks its kinase activity.
TOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Negative regulation can disrupt this interaction or recruit inhibitory proteins that lower TORC1 catalytic output. The TSC complex and its downstream small GTPase Rheb are canonical upstream brakes; when active, they keep Rheb in a state that cannot stimulate TORC1. Pharmacological inhibition by rapamycin also falls under this conceptual umbrella, as it acutely suppresses TORC1-dependent phosphorylation events.
Dephosphorylation of TOR substrates
In simple terms: Even if TOR was active moments ago, phosphatases can erase the phosphate marks it left on its targets.
Negative regulation of TOR signaling includes the reversal of activating phosphorylations on TOR substrates such as S6K1 and 4E-BP1. When TORC1 activity falls, protein phosphatases remove these marks, switching off translation initiation and ribosome biogenesis. This layer ensures that pathway output tracks the current signaling state rather than persisting after the initial stimulus has passed. Measuring phospho-S6K1 and phospho-4E-BP1 is therefore a standard way to quantify negative regulation of TOR signaling.
Feedback loops that attenuate upstream inputs
In simple terms: The pathway can also shut itself down by sending a signal back to its own upstream activators.
A major mechanism of negative regulation is feedback inhibition. PI3K signaling controls PTEN translation to maintain pathway homeostasis, meaning that upstream activation is self-limited by the very pathway it stimulates. In plants, a negative feedback loop of TOR signaling balances growth and stress-response trade-offs, demonstrating that feedback is a conserved design principle. Such loops prevent runaway activation and are frequently disrupted in cancer, where loss of feedback contributes to sustained TOR output.
Stress- and infection-coupled suppression
In simple terms: Stress or infection can force the cell to dial down TOR signaling as part of a defensive response.
Negative regulation of TOR signaling is also engaged during viral infection and immune challenge. The mitochondrial protein LRPPRC negatively regulates MAVS-mediated antiviral signaling during hepatitis C virus infection, linking TOR-associated metabolic control to innate immunity. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication, showing how pathogens co-opt autophagy and TOR-linked processes to evade host defenses. These examples illustrate that negative regulation of TOR signaling is not only a growth-control mechanism but also an immune-metabolic checkpoint.
Key Genes Involved in GO:0032007 negative regulation of TOR signaling
The following genes and proteins are experimentally and conceptually linked to negative regulation of TOR signaling, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TSC1 | Forms the TSC complex that inhibits Rheb and TORC1 | Loss causes hyperactive TOR signaling and tumor predisposition |
| TSC2 | Catalytic partner of TSC1 in restraining TORC1 | Central negative regulator mutated in tuberous sclerosis |
| PTEN | Lipid phosphatase that opposes PI3K and limits TOR activation | Translationally regulated by PI3K to maintain homeostasis |
| DDIT4 (REDD1) | Hypoxia-inducible inhibitor of mTORC1 | Target of miR-7 in hypoxia-induced mTOR regulation |
| RPTOR (raptor) | Scaffold of TORC1 that determines substrate specificity | Nutrient-sensitive partner of mTOR |
| MTOR | Kinase at the core of TORC1 and TORC2 | Primary target of rapamycin and negative regulation |
| RHEB | Small GTPase that activates TORC1 | Downstream node inhibited by TSC complex |
| RPS6KB1 (S6K1) | TORC1 substrate controlling translation | Phospho-S6K1 is a readout of TOR suppression |
| EIF4EBP1 (4E-BP1) | TORC1 substrate that gates cap-dependent translation | Phospho-4E-BP1 reports negative regulation of TOR |
| LRPPRC | Mitochondrial protein that negatively regulates MAVS signaling | Links TOR-associated metabolism to antiviral immunity |
| YTHDF2 | m6A reader degraded via autophagy during viral infection | Modulates IRF3 activity and viral replication |
| IRF3 | Transcription factor driving antiviral interferon responses | Downstream of YTHDF2 and autophagy during infection |
| MAVS | Mitochondrial antiviral signaling adaptor | Negatively regulated by LRPPRC during HCV infection |
| MIR7 (miR-7) | MicroRNA targeting REDD1 | Hypoxia-induced modulator of mTOR signaling |
| INS/IGF1 axis | Growth-factor inputs upstream of TOR | Context for feedback regulation of TOR |
| FOXO | Transcription factors inhibited by TORC1 | Mediate growth arrest when TOR is suppressed |
| Autophagy machinery | Degradative pathway induced when TORC1 is low | Effector of negative regulation of TOR signaling |
How Is negative regulation of TOR signaling Regulated?
Negative regulation of TOR signaling is itself regulated at multiple levels. Upstream, PI3K signaling controls PTEN translation to maintain pathway homeostasis, creating a feedback node that adjusts the strength of TOR inhibition. Hypoxia induces miR-7, which targets REDD1 and thereby modulates mTOR signaling, adding a microRNA layer to negative regulation. In plants, a negative feedback loop of TOR signaling balances growth and stress-response trade-offs, indicating that transcriptional and post-transcriptional feedback is a conserved feature. Viral infection can also rewire negative regulation: FMDV VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication, and LRPPRC negatively regulates MAVS-mediated antiviral signaling during HCV infection. Finally, pharmacological agents such as rapamycin impose exogenous negative regulation and are widely used to study pathway output.
negative regulation of TOR signaling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTEN | Cancer and PI3K-AKT-TOR hyperactivation | PTEN knockout or point-mutation cancer cell lines |
| TSC1/TSC2 | Tuberous sclerosis and mTOR-driven tumors | TSC2 knockout iPSC-derived neurons or renal cells |
| LRPPRC | Hepatitis C virus immune evasion | LRPPRC knockout hepatoma cells with HCV infection |
| YTHDF2 | Viral replication and IRF3 regulation | YTHDF2 knockout cells with FMDV infection |
| DDIT4 (REDD1) | Hypoxia-associated metabolic stress | REDD1 knockout or miR-7 overexpression models |
Cancer and loss of TOR brakes
Many cancers arise when negative regulation of TOR signaling is weakened. Loss of PTEN or TSC1/TSC2 removes critical brakes on PI3K-AKT-TOR signaling, leading to unrestrained translation and proliferation. Because PI3K signaling controls PTEN translation to maintain pathway homeostasis, disruption of this feedback further amplifies TOR output. Experimental models that restore negative regulation, for example by re-expressing PTEN or inhibiting TORC1, are therefore central to cancer research.
Viral infection and immune evasion
Viruses frequently manipulate negative regulation of TOR signaling to evade host immunity. The mitochondrial protein LRPPRC negatively regulates MAVS-mediated antiviral signaling during hepatitis C virus infection, dampening innate immune responses. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication, linking autophagic degradation and TOR-linked metabolism to interferon control. These findings position negative regulation of TOR signaling as a therapeutic target in antiviral strategies.
Metabolic and reproductive disorders
Negative regulation of TOR signaling also shapes metabolic and reproductive physiology. In a dehydroepiandrosterone-induced polycystic ovary syndrome mouse model, rapamycin treatment altered ovarian follicle development, demonstrating that suppressing TOR signaling has measurable effects on reproductive tissue. Because TOR integrates nutrient and hormonal cues, disorders of energy balance can perturb the negative regulation arm of the pathway, with consequences for fertility and metabolic health.
Aging and lifespan control
Modulation of genes in the TOR signaling pathway regulates lifespan in Drosophila, establishing negative regulation of TOR signaling as a conserved longevity mechanism. Reducing TOR output mimics dietary restriction and extends lifespan in model organisms, whereas hyperactivation accelerates age-related phenotypes. This has motivated research into pharmacological and genetic interventions that enhance negative regulation of TOR signaling.
From negative regulation of TOR signaling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene a negative regulator of TOR signaling? | CRISPR knockout in HEK293T or cancer cell lines with phospho-S6K1 readout |
| Does a specific phosphorylation site control negative regulation? | Point-mutation knock-in of phospho-dead or phospho-mimetic residues |
| Does a disease variant alter TOR suppression? | Knock-in of patient-derived variants followed by rapamycin challenge |
| Where does a negative regulator localize and interact? | Endogenous tagged knock-in with imaging and co-immunoprecipitation |
| Does overexpression of a brake suppress TOR-driven growth? | Doxycycline-inducible overexpression in TOR-hyperactive cells |
| Which genes mediate lifespan effects of TOR suppression? | Drosophila genetic models with TOR pathway modulation |
How to Study the negative regulation of TOR signaling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-immunoblot | Phospho-S6K1 and phospho-4E-BP1 levels | Quantify TORC1 suppression after perturbation |
| Rapamycin challenge | Sensitivity of cells to TOR inhibition | Assess negative regulation capacity |
| RNA-seq | Transcriptional changes under TOR suppression | Identify pathway signatures and feedback genes |
| Ribo-seq | Translational efficiency changes | Measure cap-dependent translation output |
| Co-immunoprecipitation / MS | Protein-protein interactions | Map TOR complex and regulator interactions |
| Autophagy flux imaging | LC3 lipidation and autophagosome formation | Confirm downstream TOR suppression |
| CRISPR knockout | Loss-of-function phenotype | Test causality of candidate negative regulators |
| Reporter assays | Pathway-responsive transcription | Screen for modifiers of TOR signaling |
Phospho-signaling assays
Because negative regulation of TOR signaling is defined by reduced pathway output, phospho-specific immunoblotting or immunofluorescence against S6K1, 4E-BP1, and AKT is a first-line method. These readouts capture the immediate consequence of TORC1 inhibition and are widely used with rapamycin treatment or genetic perturbation.
Transcriptomic and translatomic profiling
RNA-seq and Ribo-seq can reveal how negative regulation of TOR signaling reshapes gene expression and translation efficiency. Genes induced when TOR is suppressed, such as autophagy-related and stress-response genes, provide functional signatures. In plants, such profiling has been used to show that a negative feedback loop of TOR signaling balances growth and stress-response trade-offs.
Proteomics and interactomics
Affinity purification and mass spectrometry identify proteins that associate with TOR complexes or with negative regulators such as LRPPRC and YTHDF2. These approaches map the physical wiring of negative regulation and can uncover new inhibitory subunits or adaptors.
Imaging and autophagy flux
Live-cell imaging of LC3 or autophagic flux reports the downstream consequence of TOR suppression, since autophagy is induced when TORC1 is inhibited. Imaging can also localize negative regulators to mitochondria or other compartments, as shown for LRPPRC and MAVS signaling.
How CRISPR Can Be Used to Study GO:0032007 negative regulation of TOR signaling
Knockout
CRISPR knockout is the most direct way to test whether a gene is required for negative regulation of TOR signaling. Deleting candidate brakes such as PTEN or TSC2 in cell lines leads to elevated phospho-S6K1 and phospho-4E-BP1, confirming loss of negative regulation. Knockout models are also used to study viral proteins that manipulate autophagy and TOR-linked immunity.
Point Mutation
Point-mutation knock-in allows precise interrogation of phosphorylation sites, catalytic residues, or disease variants within negative regulators. For example, phospho-dead or phospho-mimetic mutations in TSC2 or PTEN can reveal how specific residues tune TOR suppression. Such models are essential when complete knockout is lethal or confounds interpretation.
Knock-in
Knock-in of epitope tags or fluorescent reporters at endogenous loci enables tracking of negative regulators in their native context. Tagged knock-in of LRPPRC or YTHDF2 supports imaging and interactomics studies that link these proteins to TOR-associated immune signaling. Disease-variant knock-in models further connect genotype to pathway output.
Overexpression
Overexpression of candidate negative regulators tests sufficiency: if a gene truly brakes TOR signaling, its overexpression should lower phospho-S6K1 and inhibit growth. Inducible overexpression systems are particularly useful in TOR-hyperactive cancer cells, where restoring a brake can suppress proliferation. Overexpression of miR-7 or REDD1 similarly modulates mTOR under hypoxia.
How EDITGENE Supports negative regulation of TOR signaling Research
Researchers studying negative regulation of TOR signaling-related genes often need to determine whether a candidate gene is causally involved in restraining pathway output, or whether its association is merely correlative. Answering that question requires precise genetic models that can remove, modify, or amplify the gene of interest in disease-relevant cells, coupled with quantitative readouts of TOR activity such as phospho-S6K1 and phospho-4E-BP1.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of TOR signaling research.
Frequently Asked Questions About negative regulation of TOR signaling
What is negative regulation of TOR signaling (GO:0032007)?
It is any process that stops, prevents, or reduces the frequency, rate or extent of TOR signaling, the conserved growth-control pathway centered on the TOR kinase.
What genes are involved in negative regulation of TOR signaling?
Key genes include TSC1, TSC2, PTEN, DDIT4 (REDD1), LRPPRC, YTHDF2, and microRNAs such as miR-7, all of which can dampen TOR pathway output.
How is TOR signaling negatively regulated by nutrients?
Nutrient and energy sensors transmit inhibitory signals to TORC1 when resources are scarce, reducing phosphorylation of substrates such as S6K1 and 4E-BP1.
What is the role of PTEN in negative regulation of TOR signaling?
PTEN opposes PI3K signaling and limits TOR activation; its translation is itself controlled by PI3K to maintain pathway homeostasis.
How does rapamycin relate to negative regulation of TOR signaling?
Rapamycin pharmacologically inhibits TORC1 and is widely used to mimic or study negative regulation of TOR signaling in cells and animal models.
Can viruses manipulate negative regulation of TOR signaling?
Yes; hepatitis C virus and foot-and-mouth disease virus can alter proteins such as LRPPRC and YTHDF2 to modulate antiviral signaling and autophagy.
How do you measure negative regulation of TOR signaling experimentally?
Common readouts include phospho-S6K1, phospho-4E-BP1, phospho-AKT, rapamycin sensitivity, and autophagy flux assays.
Is negative regulation of TOR signaling important for aging?
Yes; modulation of TOR pathway genes regulates lifespan in Drosophila, linking negative regulation of TOR signaling to longevity.
What CRISPR models are used to study negative regulation of TOR signaling?
Knockout, point-mutation, knock-in, and overexpression models are used to test causality and sufficiency of candidate regulators.
Which diseases involve defective negative regulation of TOR signaling?
Cancer, viral immune evasion, metabolic and reproductive disorders, and age-related phenotypes have all been linked to altered TOR suppression.
Conclusion
GO:0032007, negative regulation of TOR signaling, defines the essential brakes that keep a central growth pathway within physiological bounds. From feedback loops involving PTEN and TSC1/TSC2 to stress- and infection-coupled regulators such as REDD1, LRPPRC, and YTHDF2, these mechanisms shape cancer, immunity, metabolism, reproduction, and aging. Because the term is defined by reduced pathway output, it is best studied with quantitative phospho-signaling readouts combined with precise genetic perturbation. CRISPR knockout, point-mutation, knock-in, and overexpression models, together with library screening and bioinformatics, provide a rigorous route to identify and validate negative regulators of TOR signaling in any disease context.
References
- 1. Jamsheer K M et al.. 2022. A negative feedback loop of TOR signaling balances growth and stress-response trade-offs in plants.. Cell Rep 39(1):110631 PMID: 35385724
- 2. Liu H et al.. 2024. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication.. Autophagy 20(7):1597-1615 PMID: 38516932
- 3. Refolo G et al.. 2019. Negative Regulation of Mitochondrial Antiviral Signaling Protein-Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection.. Hepatology 69(1):34-50 PMID: 30070380
- 4. Kim DH et al.. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.. Cell 110(2):163-75 PMID: 12150925
- 5. Mukherjee R et al.. 2021. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis.. Mol Cell 81(4):708-723.e5 PMID: 33606974
- 6. Yildirim E et al.. 2024. The effect of rapamycin treatment on mouse ovarian follicle development in dehydroepiandrosterone-induced polycystic ovary syndrome mouse model.. Zygote 32(5):386-395 PMID: 39498504
- 7. Kapahi P et al.. 2004. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.. Curr Biol 14(10):885-90 PMID: 15186745
- 8. Seong M et al.. 2019. Hypoxia-induced regulation of mTOR signaling by miR-7 targeting REDD1.. J Cell Biochem 120(3):4523-4532 PMID: 30302791
